Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

Early prediction of neoadjuvant treatment outcome in locally advanced breast cancer using parametric response mapping and radial heterogeneity from breast MRI.

Auteurs : Drisis S, El Adoui M, Flamen P, Benjelloun M, Dewind R, Paesmans M, Ignatiadis M, Bali M, Lemort M
Jaar : 2020
Journal : J Magn Reson Imaging
Volume : 51
Pagina's : 1403-1411

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

Auteurs : Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart-Gebhart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A
Jaar : 2020
Journal : Eur J Cancer
Volume : 125
Pagina's : 69-82

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Auteurs : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Jaar : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pagina's : 69-77

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Auteurs : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Jaar : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pagina's : 86-94

Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

Auteurs : Brandão M, Coens C, Ignatiadis M
Jaar : 2019
Journal : Ann Oncol
Volume : 30
Pagina's : 1677-1681

Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.

Auteurs : Rossi G, Ignatiadis M
Jaar : 2019
Journal : Cancer Res
Volume : 79
Pagina's : 2798-2804

Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

Auteurs : Brandão M, Coens C, Ignatiadis M
Jaar : 2019
Journal : Ann Oncol
Volume : 30
Pagina's : 1677-1681

CANCER DU SEIN AVEC MÉTASTASE INHABITUELLE AU NIVEAU VÉSICAL : RAPPORT DE CAS ET REVUE SYSTÉMATIQUE DE LA LITTÉRATURE

Auteurs : Marcoux D, Ignatiadis M, Paesmans M, Awada A
Jaar : 2019
Journal : Rev Med Brux
Volume : 40(3)
Pagina's : 148-159

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Auteurs : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Jaar : 2019
Journal : BMC Cancer
Volume : 19
Pagina's : 304

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Auteurs : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Jaar : 2019
Journal : Clin Cancer Res
Volume : 25
Pagina's : 3581-3588

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Auteurs : Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, Van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K
Jaar : 2019
Journal : Crit Rev Oncol Hematol
Volume : 134
Pagina's : 39-45

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Auteurs : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Jaar : 2019
Journal : Support Care Cancer
Volume : 27
Pagina's : 1163-1170

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Jaar : 2019
Journal : Cancer
Volume : 125
Pagina's : 307-316

Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: The impact of immunohistochemical status.

Auteurs : Drisis S, Flamen P, Ignatiadis M, Metens T, Chao SL, Chintinne M, Lemort M
Jaar : 2018
Journal : J Magn Reson Imaging
Volume : 48(4)
Pagina's : 982-993

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Auteurs : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pagina's : 560-567

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Auteurs : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Jaar : 2018
Journal : Ann Oncol
Volume : 29(4)
Pagina's : 895-902

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Auteurs : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Jaar : 2018
Journal : Ann Oncol
Volume : 29(8)
Pagina's : 1777-1783

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.

Auteurs : Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, Jensen MB, Gelber S, Del Grande M, Ignatiadis M, de Azambuja E, Paesmans M, Peccatori FA, Azim HA Jr
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(4)
Pagina's : 426-429

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.

Auteurs : Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, Delbaere A, tKint de Roodenbeke MD, de Azambuja E, Ignatiadis M, Demeestere I
Jaar : 2018
Journal : Ann Oncol
Volume : 29(1)
Pagina's : 237-243

CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?

Auteurs : Brandão M, Ignatiadis M
Jaar : 2018
Journal : Ann Oncol
Volume : 29(12)
Pagina's : 2274-2278